RESUMO
BACKGROUND: Continuous ambulatory peritoneal dialysis (CAPD) is the first option for patients with end-stage renal disease under the benefit package of Thailand. Nevertheless, automated peritoneal dialysis (APD) may benefit these patients in terms of both medical and quality-of-life aspects, but it is more expensive. The economic evidence for the comparison between CAPD and APD is not inconclusive. Thus, this study aims to evaluate the cost-effectiveness of CAPD compared with APD in PD patients. OBJECTIVES: To assess the health-related quality of life and costs between patients treated with CAPD and APD. METHODS: A Markov model was developed to evaluate the cost-effectiveness of CAPD and APD from the societal perspective. Costs and outcomes were calculated over a lifetime horizon and discounted at an annual rate of 3%. The outcomes were presented as quality-adjusted life-years (QALYs) of CAPD and APD. Utility scores were calculated from the utility values of the 5-level EuroQol questionnaire. A probabilistic sensitivity analysis using 5000 Monte Carlo simulations was performed to evaluate the stability of the results. RESULTS: The costs of APD and CAPD were 12 868 080 and 11 144 786 Thai baht, respectively, whereas the QALYs were 24.28 and 24.72 QALYs, respectively. APD was more costly but less effective than CAPD. The most sensitive parameter was direct medical cost of outpatient visits. When the willingness-to-pay threshold was 160 000 Thai baht per QALY, the probability of APD providing a cost-effective alternative to CAPD was 19%. CONCLUSION: APD was not a cost-effective strategy as compared with CAPD at the current Thai threshold. These findings should encourage clinicians and policy makers to encompass the use of CAPD as a good value for money for PD treatment.
Assuntos
Análise Custo-Benefício/estatística & dados numéricos , Falência Renal Crônica/terapia , Diálise Peritoneal Ambulatorial Contínua/economia , Idoso , Idoso de 80 Anos ou mais , Instituições de Assistência Ambulatorial/organização & administração , Instituições de Assistência Ambulatorial/estatística & dados numéricos , Automação/instrumentação , Automação/métodos , Análise Custo-Benefício/métodos , Feminino , Humanos , Falência Renal Crônica/epidemiologia , Masculino , Pessoa de Meia-Idade , Modelos Teóricos , Diálise Peritoneal Ambulatorial Contínua/métodos , Diálise Peritoneal Ambulatorial Contínua/estatística & dados numéricos , Anos de Vida Ajustados por Qualidade de Vida , Inquéritos e Questionários , Tailândia/epidemiologiaRESUMO
OBJECTIVES: In Malaysia, there is exponential growth of patients on dialysis. Dialysis treatment consumes a considerable portion of healthcare expenditure. Comparative assessment of their cost effectiveness can assist in providing a rational basis for preference of dialysis modalities. METHODS: A cost utility study of hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) was conducted from a Ministry of Health (MOH) perspective. A Markov model was also developed to investigate the cost effectiveness of increasing uptake of incident CAPD to 55% and 60% versus current practice of 40% CAPD in a five-year temporal horizon. A scenario with 30% CAPD was also measured. The costs and utilities were sourced from published data which were collected as part of this study. The transitional probabilities and survival estimates were obtained from the Malaysia Dialysis and Transplant Registry (MDTR). The outcome measures were cost per life year (LY), cost per quality adjusted LY (QALY) and incremental cost effectiveness ratio (ICER) for the Markov model. Sensitivity analyses were performed. RESULTS: LYs saved for HD was 4.15 years and 3.70 years for CAPD. QALYs saved for HD was 3.544 years and 3.348 for CAPD. Cost per LY saved was RM39,791 for HD and RM37,576 for CAPD. The cost per QALY gained was RM46,595 for HD and RM41,527 for CAPD. The Markov model showed commencement of CAPD in 50% of ESRD patients as initial dialysis modality was very cost-effective versus current practice of 40% within MOH. Reduction in CAPD use was associated with higher costs and a small devaluation in QALYs. CONCLUSIONS: These findings suggest provision of both modalities is fiscally feasible; increasing CAPD as initial dialysis modality would be more cost-effective.
Assuntos
Custos de Cuidados de Saúde , Falência Renal Crônica/economia , Modelos Econômicos , Diálise Peritoneal Ambulatorial Contínua/economia , Anos de Vida Ajustados por Qualidade de Vida , Sistema de Registros , Análise Custo-Benefício , Feminino , Humanos , Malásia , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Despite growing need, treatment for end-stage renal disease is limited in low- and middle-income countries due to resource restraints. We describe the development of an educational curriculum and quality improvement program to support continuous ambulatory peritoneal dialysis (CAPD) performed primarily by non-nephrology providers in Sri Lanka. METHODS: We developed a program of education, outcome tracking, and expert consultation to support providers in Kandy, Sri Lanka. Education included videos and in-person didactics covering core topics in CAPD. Event-tracking sheets recorded root causes and management of infections and hospitalizations. Conferences reviewed clinical cases and overall clinic management. We evaluated the patient census, peritonitis rates, and root causes and management of infections over 1 year. RESULTS: The curriculum was published through the International Society of Nephrology online academy. High provider turnover limited curriculum assessments. The CAPD patient census rose from 63 to 116 during the year. The peritonitis rate declined significantly, from 0.8 episodes per patient-year in the first 6 months to 0.4 in the latter 6 months, though the most common root causes of peritonitis, related to contamination events and hygiene, persisted. The appropriate ascertainment of culture data and prescription of antibiotics also increased. CONCLUSIONS: Our project supported the expansion of a CAPD program in a resource-limited setting, while also improving peritonitis outcomes. Ongoing challenges include ensuring a durable educational system for rotating providers, tracking outcomes beyond peritonitis, and formalizing management protocols. Our program can serve as an example of how established dialysis programs can support the burgeoning work of providers in resource-limited setting.
Assuntos
Educação a Distância/métodos , Falência Renal Crônica/terapia , Educação de Pacientes como Assunto/métodos , Diálise Peritoneal Ambulatorial Contínua/economia , Melhoria de Qualidade , Adulto , Idoso , Feminino , Humanos , Falência Renal Crônica/economia , Masculino , Pessoa de Meia-Idade , Fatores Socioeconômicos , Sri Lanka , Gravação em Vídeo , Adulto JovemRESUMO
End-stage renal disease (ESRD) is common in the elderly population, and renal replacement therapy (RRT) is often required. However, in this particular subgroup of patients, the choice between hemodialysis (HD) and peritoneal dialysis (PD) is often not an easy decision to make. Published literature has adequately demonstrated that PD prevalence is significantly less than HD across all patient age groups despite several advantages. We also know that elderly patients are less likely to complete a PD assessment, due to both medical and social barriers. Additionally, elderly patients are often reluctant to go ahead with PD despite being eligible PD candidates, mainly due to the fear of performing self-therapy. Recently, many new assisted PD (asPD) programs have cropped up in several countries. The main aim of these programs is to overcome barriers to PD and to promote PD utilization among elderly and non-self-sufficient patients. Although asPD has proven to be associated with good clinical results, there still remain concerns about its greater use. In this review, we will first describe an ideal asPD model and then enumerate examples of strategies and outcomes associated with successful asPD programs worldwide.
Assuntos
Custos de Cuidados de Saúde , Falência Renal Crônica/terapia , Diálise Peritoneal Ambulatorial Contínua/métodos , Idoso , Cuidadores , Comportamento de Escolha , Serviços de Assistência Domiciliar , Humanos , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Diálise Peritoneal Ambulatorial Contínua/economiaRESUMO
OBJECTIVES: Taiwan succeeded in raising the proportion of peritoneal dialysis (PD) usage after the National Health Insurance (NHI) payment scheme introduced financial incentives in 2005. This study aims to compare the economic costs between automated PD (APD) and continuous ambulatory PD (CAPD) modalities from a societal perspective. DESIGN AND SETTING: A retrospective cohort of patients receiving PD from the NHI Research Database was identified during 2004-2011. The 1:1 propensity score matched 1749 APD patients and 1749 CAPD patients who were analysed on their NHI-financed medical costs and utilisation. A multicentre study by face-to-face interviews on 117 APD and 129 CAPD patients from five hospitals located in four regions of Taiwan was further carried out to collect data on their out-of-pocket payments, productivity losses and quality of life with EuroQol-5D-5L. OUTCOME MEASURES: The NHI-financed medical costs, out-of-pocket payments and productivity losses of APD and CAPD patients. RESULTS: The total NHI-financed medical costs per patient-year after 5â years of follow-up were significantly higher with APD than CAPD (US$23â 005 vs US$19â 237; p<0.01). In terms of dialysis-related costs, APD had higher costs resulting from the use of APD machines (US$795) and APD sets (US$2913). Significantly lower productivity losses were found with APD (US$2619) than CAPD (US$6443), but the out-of-pocket payments were not significantly different. The differences in NHI-financed medical costs and productivity losses between APD and CAPD remained robust in the bootstrap analysis. The total economic costs of APD (US$30â 401) were similar to those of CAPD (US$29â 939), even after bootstrap analysis (APD, US$28â 399; CAPD, US$27â 960). No discernable differences were found in the results of mortality and quality of life between the APD and CAPD patients. CONCLUSIONS: APD had higher annual dialysis-related costs and lower annual productivity losses than CAPD, which made the economic costs of APD very close to those of CAPD in Taiwan.
Assuntos
Custos de Cuidados de Saúde , Falência Renal Crônica/terapia , Diálise Peritoneal/economia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Gastos em Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Diálise Peritoneal/métodos , Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/métodos , Qualidade de Vida , Estudos Retrospectivos , Medicina Estatal , Inquéritos e Questionários , Taiwan , Adulto JovemRESUMO
⦠BACKGROUND: There is little information regarding the financial burden of peritonitis and the economic impact of continuous quality improvement (CQI) programs in peritoneal dialysis (PD) patients. The objectives of this study were to measure the costs of peritonitis, and determine the net savings of a PD CQI program in Colombia. ⦠METHODS: The Renal Therapy Services (RTS) network in Colombia, along with Coomeva EPS, provided healthcare resource utilization data for PD patients with and without peritonitis between January 2012 and December 2013. Propensity score matching and regression analysis were performed to estimate the incremental cost of peritonitis. Patient months at risk, episodes of peritonitis pre- and post-CQI, and costs of CQI were obtained. Annual net savings of the CQI program were estimated based on the number of peritonitis events prevented. ⦠RESULTS: The incremental cost of a peritonitis episode was $250. In an 8-year period, peritonitis decreased from 1,837 episodes per 38,596 patient-months in 2006 to 841 episodes per 50,910 patient-months in 2014. Overall, the CQI program prevented an estimated 10,409 episodes of peritonitis. The cost of implementing the CQI program was $147,000 in the first year and $119,000 annually thereafter. Using a five percent discount rate, the net present value of the program was $1,346,431, with an average annual net savings of $207,027. The return on investment (i.e. total savings-program cost/program cost) of CQI was 169%. ⦠CONCLUSION: Continuous quality improvement initiatives designed to reduce rates of peritonitis have a strong potential to generate cost savings.
Assuntos
Custos de Cuidados de Saúde , Falência Renal Crônica/terapia , Diálise Peritoneal/economia , Peritonite/economia , Melhoria de Qualidade/organização & administração , Adulto , Idoso , Estudos de Coortes , Colômbia , Análise Custo-Benefício , Bases de Dados Factuais , Feminino , Humanos , Falência Renal Crônica/diagnóstico , Falência Renal Crônica/economia , Masculino , Pessoa de Meia-Idade , Diálise Peritoneal/efeitos adversos , Diálise Peritoneal/métodos , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/métodos , Peritonite/etiologia , Peritonite/prevenção & controle , Avaliação de Programas e Projetos de Saúde , Estudos RetrospectivosRESUMO
BACKGROUND: Prior to 2003 in Bangladesh, ~ 80% of kidney-failure patients could not afford treatment. The Kidney Foundation Bangladesh (KFB) was formed in 2003 with an aim to create awareness, to promote prevention of kidney disease to families and population, at risk as well as offer treatment to those afflicted with kidney failure. METHODS: KFB runs a 150-bed hospital for treatment of kidney disease, dialysis, and transplantation at an affordable price. New patients visiting the OPD pay only US$ 5.00 to consult a specialist, and dialysis and transplant patients pay US$1 for each consultation. All laboratory tests are discounted by 30% for all patients except patients with dialysis and transplantation who enjoy a 50% discount. Patients on HD pay only US$ 20.00 per session, and a renal transplant surgery costs US$ 3,000.00. RESULTS: From October 2004 to December 2014, there were 102,578 patients who received treatment in OPD in KFB at an affordable price. Similarly, more than 40,000 people per year benefited from various laboratory tests. A total of 11,099 patients were admitted in KFB hospital from January 2010 to December 2014. Of them, 2,409 (22%) were diagnosed as ESRD, and all of them were initially managed with dialysis either through a noncuffed catheter (82%) or by an AV fistula (8%); of the 388 continued on HD, 300 underwent transplantation, 289 agreed to shift to CAPD treatment, and rest of the patients were shifted to other HD centers. Simultaneously, a total of 3,600 patients were screened in rural, urban, and disadvantaged populations from 2004 to 2007 for detection of CKD. CONCLUSION: KFB is offering treatment for patients with kidney disease and kidney failure, not only at an affordable price, but also without compromising quality.
Assuntos
Fundações , Nefropatias/terapia , Insuficiência Renal/terapia , Bangladesh/epidemiologia , Custos de Cuidados de Saúde , Promoção da Saúde , Recursos em Saúde , Preços Hospitalares , Hospitais Especializados , Humanos , Nefropatias/epidemiologia , Nefropatias/prevenção & controle , Falência Renal Crônica/epidemiologia , Falência Renal Crônica/terapia , Transplante de Rim/economia , Transplante de Rim/estatística & dados numéricos , Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/estatística & dados numéricos , Diálise Renal/economia , Diálise Renal/estatística & dados numéricos , Insuficiência Renal/epidemiologia , Insuficiência Renal/prevenção & controle , Populações VulneráveisRESUMO
According to latest data published by the French health authority (HAS), nearly 74,000 French patients in end-stage chronic renal disease are following a replacement therapy. They were 61,000 in 2007, amounting to a cost of 4 billions euros for public health insurance. The cost varies depending on the age and comorbidities. Continuous ambulatory peritoneal dialysis is the cheapest mode of treatment, while the heavy haemodialysis centres costs are close to twice as expensive. But these two different treatments are - a priori - not applied for the same patients in terms of level of severity of disease. Moreover, associated costs, medical treatment, transportation, etc. are to be taken into account, as well as losses of income for patients facing major job difficulties. As recommended by HAS experts, it will be important to regularly conduct surveys allowing a regular economic assessment of the various modes of financial healthcare for end-stage chronic renal disease.
Assuntos
Custos e Análise de Custo , Atenção à Saúde/economia , Falência Renal Crônica/economia , Falência Renal Crônica/terapia , Diálise Peritoneal Ambulatorial Contínua/economia , Adolescente , Adulto , Idoso , França , Humanos , Pessoa de Meia-Idade , Diálise Peritoneal Ambulatorial Contínua/métodos , Qualidade de Vida , Resultado do TratamentoRESUMO
UNLABELLED: ⦠BACKGROUND: Cost is always a big issue for dialysis patients. In the present study, we analyzed the effect of different payment schemes on dialysis adequacy and clinical outcome in our peritoneal dialysis program. ⦠METHODS: This is a single-center cohort study. A total of 175 patients who began dialysis from January 2006 to December 2007 were included. Baseline data, including volume status, dietary intake and nutrition status, dialysis adequacy, and sodium removal were collected at 6 months after peritoneal dialysis. Based on the different payment schemes, the patients were divided into 2 groups, higher payment group (GHP, 130 cases, with more than 85% reimbursement), and lower payment group (GLP, 45 cases, with less than 50% payment or totally self-paid). Patients were followed up until dropout or until December 31, 2013. ⦠RESULTS: At baseline, patients in the 2 groups had nearly the same residual renal function. But the GLP group patients dialyzed at a lower dose (4,516.91 ± 1,768.20 mL vs 6,058.17 ± 2,013.43 mL, p < 0.001). They had lower creatinine clearance (51.64 ± 24.23 L/w vs 70.54 ± 30.27 L/w, p < 0.001), sodium removal (2.23 ± 1.29 g vs 2.77 ± 1.29 g, p = 0.027), and fluid removal (970.33 ± 545.97 mL vs 1,146.66 ± 460.93 mL, p = 0.038). Normalized by height (in meters), the GLP group patients still had a lower normalized dialysis dose (2,890.61 ± 1084.44 mL/m vs 3,761.34 ± 1,237.10 mL/m, p < 0.001). Baseline nutritional and dietary parameters were comparable except that a lower daily protein intake (42.73 ± 10.99 g vs 47.26 ± 14.30 g, p = 0.032) and higher serum urea level (23.43 ± 6.88 mmol/L vs 19.84 ± 5.92 mmol/L, p < 0.001) were presented in the GLP group. There was no difference in volume status. During the follow-up, Kaplan-Meier analysis showed that there was no significant difference in patient survival and technique survival. In multivariate Cox regression analysis, after adjusting for related factors, payment was again not a strong predictor of survival in the study population. ⦠CONCLUSION: Our study found that GLP group patients were adherent to lifestyle modification with lower dialysis doses, and they also had nearly the same long-term clinical outcome as the GHP group patients. Thus, lower dialysis doses combined with controlled dietary intake may be an effective approach to solve the dialysis problem for the low socio-economic status (SES) population.
Assuntos
Gastos em Saúde/estatística & dados numéricos , Falência Renal Crônica/terapia , Diálise Peritoneal Ambulatorial Contínua/economia , Adulto , Idoso , Estudos de Coortes , Dieta , Feminino , Seguimentos , Estilo de Vida Saudável , Humanos , Rim/fisiopatologia , Falência Renal Crônica/economia , Masculino , Pessoa de Meia-Idade , Pacientes , Diálise Peritoneal Ambulatorial Contínua/métodos , Diálise Peritoneal Ambulatorial Contínua/mortalidade , Análise de Regressão , Análise de Sobrevida , Resultado do TratamentoRESUMO
AIM: This study aimed to evaluate the cost-effectiveness of haemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) for patients with end-stage renal disease (ESRD) in Singapore. METHODS: A Markov model was developed to examine the incremental cost-effectiveness ratios (ICERs) of HD, CAPD and APD over the 10-year time horizon from the societal perspective, using clinical data from an observational study and the national renal registry, utilities from published studies and costs from dialysis services providers. The base-case analysis was for a hypothetical cohort of 60-year-old non-diabetic ESRD patients. A high-risk group of 60-year-old diabetic ESRD patients was also studied. RESULTS: In the base-case analysis, the quality-adjusted life-years (QALYs) were 3.27 with CAPD, 3.48 with APD and 4.69 with HD. The total costs were Singapore dollar $169 872 for CAPD, $201 509 for APD and $306 827 for HD. CAPD and HD had extended dominance over APD. The ICER of HD versus CAPD was $96 447 (US$69 121) per QALY. One-way sensitivity analyses indicated that the results were most sensitive to the utility of HD. Probabilistic sensitivity analyses demonstrated that CAPD had the maximum probability of being cost-effective among treatments under evaluation at a willingness-to-pay (WTP) threshold of $60 000 (US$43 000) per QALY. The high-risk group analyses showed similar results. The ICER of HD versus CAPD was $106 281 (US$76 168) per QALY and the probability of CAPD being optimal was the highest using the same WTP threshold. CONCLUSIONS: Our analysis suggested that starting dialysis with CAPD is most cost-effective for ESRD patients in Singapore.
Assuntos
Custos de Cuidados de Saúde , Falência Renal Crônica/economia , Falência Renal Crônica/terapia , Diálise Peritoneal/economia , Avaliação de Processos em Cuidados de Saúde/economia , Diálise Renal/economia , Análise Custo-Benefício , Feminino , Humanos , Falência Renal Crônica/mortalidade , Falência Renal Crônica/psicologia , Masculino , Cadeias de Markov , Pessoa de Meia-Idade , Modelos Econômicos , Estudos Observacionais como Assunto , Diálise Peritoneal/efeitos adversos , Diálise Peritoneal/mortalidade , Diálise Peritoneal Ambulatorial Contínua/economia , Anos de Vida Ajustados por Qualidade de Vida , Sistema de Registros , Diálise Renal/efeitos adversos , Diálise Renal/mortalidade , Singapura/epidemiologia , Fatores de Tempo , Resultado do TratamentoRESUMO
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, with 50-75% of these patients requiring renal replacement therapy (RRT). The outcome of peritoneal dialysis (PD) in ADPKD with end-disease renal disease (ESRD) is not clearly defined, more so in developing countries. We conducted a retrospective analysis of the outcomes and economics of PD in these ESRD patients and compared them with other causes of ESRD on PD. Data were reviewed of all the PD patients who were followed-up at our institute from January 2007 to December 2011. The inclusion criteria were ADPKD patients who chose PD as the dialysis modality (Group 1), while age and gender-matched ESRD (other than ADPKD) patients who were started on PD during the same period were considered as the other group (Group 2). A total of 26 ADPKD patients underwent PD with an average size of kidneys among ADPKD ESRD patients of 15.2 + 2.1 cm. The overall peritonitis rates were similar among the compared groups. The median survival for the first peritonitis episodes were 1.2 and 1.8 years (95% confidence interval 0.82-1.91) for the control and ADPKD groups, respectively. The overall patient survival was 22 among PKD while five patients died among the control group. Among PKD, one patient died due to intra-cerebral bleed while one patient had severe cyst hemorrhage and infection, while three others had peritonitis and sepsis. Hernia was observed in four ADPKD patients, once on PD that was surgically corrected and PD was resumed in all. Two patients lost the catheter due to peritonitis while one patient had membrane failure while one underwent surgical exploration due to diverticulosis. PD treatment was not prevented by voluminous kidneys in any of these patients and no patient ceased PD treatment due to insufficient peritoneal space. Besides this, the cost on PD was much less as compared with that on hemodialysis (HD). PD is a reasonable mode of RRT among ADPKD, where HD is not possible or contraindicated with lesser risks to bleeding and infections, and the cost benefit favoring PD in general.
Assuntos
Custos de Cuidados de Saúde , Falência Renal Crônica/economia , Falência Renal Crônica/terapia , Diálise Peritoneal Ambulatorial Contínua/economia , Rim Policístico Autossômico Dominante/economia , Rim Policístico Autossômico Dominante/terapia , Avaliação de Processos em Cuidados de Saúde/economia , Adulto , Redução de Custos , Análise Custo-Benefício , Países em Desenvolvimento/economia , Feminino , Humanos , Índia/epidemiologia , Falência Renal Crônica/diagnóstico , Falência Renal Crônica/mortalidade , Masculino , Pessoa de Meia-Idade , Modelos Econômicos , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Diálise Peritoneal Ambulatorial Contínua/mortalidade , Rim Policístico Autossômico Dominante/diagnóstico , Rim Policístico Autossômico Dominante/mortalidade , Diálise Renal/economia , Estudos Retrospectivos , Resultado do TratamentoRESUMO
BACKGROUND: Socioeconomic characteristics may affect the outcomes of patients treated with peritoneal dialysis (PD). There are two major medical insurances in China: the New Cooperative Medical Scheme (NCMS), mainly for rural residents, and the Urban Employees' Medical Insurance (UEMI). The aim of the present study was to assess the effect of medical insurance type on survival of patient undergoing PD. METHOD: This was a prospective study in adult patients who underwent PD at the Wuhan No.1 Hospital between January 2008 and December 2013. Patients had received continuous ambulatory PD for >3 months. Patients were divided according to their medical insurance. Demographic and socioeconomic data, biochemical parameters and primary clinical outcomes including all-cause mortality, switch to hemodialysis and kidney transplantation were analyzed. RESULT: There were 415 patients with UEMI and 149 with NCMS. Compared with UEMI, patients with NCMS were younger, and had shorter dialysis duration, smaller proportion of diabetic nephropathy, more severe anemia, and more frequent hyperphosphatemia and hyperuricemia. Total Kt/V, creatinine clearance and residual renal function were not different. There was no difference in technique survival (P > 0.05) between the two groups, but rural patients showed lower overall survival (P < 0.05). Multivariate analysis showed that NCMS was independently associated with lower survival (RR = 1.49; 95% CI = 1.04-2.15). CONCLUSIONS: Medical insurance model is independently associated with PD patient survival.
Assuntos
Disparidades em Assistência à Saúde/economia , Seguro Saúde/economia , Falência Renal Crônica/mortalidade , Falência Renal Crônica/terapia , Diálise Peritoneal Ambulatorial Contínua/economia , Adulto , Idoso , China , Estudos de Coortes , Feminino , Planos de Assistência de Saúde para Empregados/economia , Humanos , Estimativa de Kaplan-Meier , Falência Renal Crônica/diagnóstico , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Diálise Peritoneal/economia , Diálise Peritoneal/métodos , Diálise Peritoneal Ambulatorial Contínua/métodos , Modelos de Riscos Proporcionais , Estudos Prospectivos , Qualidade da Assistência à Saúde , População Rural , Fatores Socioeconômicos , Análise de Sobrevida , População UrbanaRESUMO
Despite the 40 years history, the comparable survival of Hemodialysis and Peritoneal Dialysis (PD), and the improved PD technique survival, the percentage of patients performing PD is low. After a short history review and data description, we analyze the many non-medical factors (“the vicious circle”) that contribute to the underutilization of PD: inadequate medical training, lack of infrastructures, small PD units, inadequate patient education for choice of dialysis modality, lack of multidisciplinary end-stage renal disease units, the proliferation of hemodialysis centers, or the trends in government reimbursement. Several of these factors are modifiable, and we propose future strategies to increase the use of PD.
Assuntos
Diálise Peritoneal/tendências , Análise Custo-Benefício , Previsões , Pessoal de Saúde/educação , Unidades Hospitalares/economia , Unidades Hospitalares/provisão & distribuição , Humanos , Falência Renal Crônica/terapia , Nefrologia/educação , Educação de Pacientes como Assunto , Diálise Peritoneal/economia , Diálise Peritoneal/estatística & dados numéricos , Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/estatística & dados numéricos , Diálise Peritoneal Ambulatorial Contínua/tendências , Diálise Renal/economia , Diálise Renal/estatística & dados numéricos , Espanha , Estados Unidos , Carga de TrabalhoRESUMO
OBJECTIVE: to determine the cost of institutional and familial care for patients with chronic kidney disease replacement therapy with continuous ambulatory peritoneal dialysis. METHODS: a study of the cost of care for patients with chronic kidney disease treated with continuous ambulatory peritoneal dialysis was undertaken. The sample size (151) was calculated with the formula of the averages for an infinite population. The institutional cost included the cost of outpatient consultation, emergencies, hospitalization, ambulance, pharmacy, medication, laboratory, x-rays and application of erythropoietin. The family cost included transportation cost for services, cost of food during care, as well as the cost of medication and treatment materials acquired by the family for home care. The analysis included averages, percentages and confidence intervals. RESULTS: the average annual institutional cost is US$ 11,004.3. The average annual family cost is US$ 2,831.04. The average annual cost of patient care in continuous ambulatory peritoneal dialysis including institutional and family cost is US$ 13,835.35. CONCLUSION: the cost of chronic kidney disease requires a large amount of economic resources, and is becoming a serious problem for health services and families. It's also true that the form of patient management in continuous ambulatory peritoneal dialysis is the most efficient in the use of institutional resources and family.
Assuntos
Efeitos Psicossociais da Doença , Diálise Peritoneal Ambulatorial Contínua/economia , Insuficiência Renal Crônica/economia , Saúde da Família , Feminino , Custos de Cuidados de Saúde , Preços Hospitalares , Humanos , Masculino , México , Pessoa de Meia-Idade , Diálise Renal/economia , Insuficiência Renal Crônica/terapiaRESUMO
Objective: to determine the cost of institutional and familial care for patients with chronic kidney disease replacement therapy with continuous ambulatory peritoneal dialysis. Methods: a study of the cost of care for patients with chronic kidney disease treated with continuous ambulatory peritoneal dialysis was undertaken. The sample size (151) was calculated with the formula of the averages for an infinite population. The institutional cost included the cost of outpatient consultation, emergencies, hospitalization, ambulance, pharmacy, medication, laboratory, x-rays and application of erythropoietin. The family cost included transportation cost for services, cost of food during care, as well as the cost of medication and treatment materials acquired by the family for home care. The analysis included averages, percentages and confidence intervals. Results: the average annual institutional cost is US$ 11,004.3. The average annual family cost is US$ 2,831.04. The average annual cost of patient care in continuous ambulatory peritoneal dialysis including institutional and family cost is US$ 13,835.35. Conclusion: the cost of chronic kidney disease requires a large amount of economic resources, and is becoming a serious problem for health services and families. It's also true that the form of patient management in continuous ambulatory peritoneal dialysis is the most efficient in the use of institutional resources and family. .
Objetivo: determinar o custo da atenção institucional e familiar do paciente com doença renal crônica terminal em tratamento substitutivo com diálise peritoneal ambulatorial contínua. Métodos: foi desenvolvido um estudo de custo da atenção com pacientes com doença crônica renal em tratamento com diálise peritoneal ambulatorial contínua. A amostra foi de 151 pessoas, calculada com a fórmula das médias para população infinita. No custo institucional foi incluído o custo da consulta externa, urgências, internamento, ambulância, farmácia, medicamentos, laboratório, raios X e administração de eritropoetina. No custo da família foi considerado o custo do traslado para receber os serviços, o custo das refeições durante a atenção, além do custo dos medicamentos e do material para curativos comprados pela família no atendimento domiciliar. A análise foi com médias, porcentagens e intervalo de confiança. Resultados: o custo anual institucional é US$11.004,3. O custo anual da família foi em média de US$2.381,04. O custo anual, em média, da atenção do paciente com diálise peritoneal ambulatorial contínua, incluindo o custo institucional e familiar, é de US$13.835,35. Conclusão: o custo da doença renal crônica requer uma grande quantidade de recursos econômicos, convertendo-se em um sério problema para os serviços de saúde e a família. .
Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Efeitos Psicossociais da Doença , Diálise Peritoneal Ambulatorial Contínua/economia , Insuficiência Renal Crônica/economia , Saúde da Família , Custos de Cuidados de Saúde , Preços Hospitalares , México , Diálise Renal/economia , Insuficiência Renal Crônica/terapiaRESUMO
BACKGROUND AND AIMS: The use of automated peritoneal dialysis (APD) is increasing compared to continuous ambulatory peritoneal dialysis (CAPD). Surprisingly, little data about health benefits and cost of APD exist, and virtually no information comparing the cost-utility between CAPD and APD is available. We undertook this study to evaluate and compare the health-related quality of life (HRQOL) and cost-utility indexes in patients on CAPD vs. APD METHODS: This was a prospective cohort of patients initiating dialysis (2008-2009). Two questionnaires were self-administered: European Research Questionnaire Quality of Life (EQ-5D) and Kidney Disease Quality of Life (short form, KDQOL-SF, Rand, Santa Monica, CA). Direct medical costs (DMC) were determined from the health provider perspective including the following medical resource utilization: outpatient clinic/emergency care, dialysis procedures, medications, laboratory tests, hospitalization, and surgery. Cost-utility indexes were calculated dividing total mean cost by indicators of the HRQOL. RESULTS: One hundred twenty-three patients were evaluated: 77 on CAPD and 46 on APD. Results of the EQ-5D and KDQOL-SF questionnaires were significantly better in APD compared to the CAPD group. Main costs in both APD and CAPD were attributed to hospitalization and dialysis procedures followed by medication and surgery. Outpatient clinic visits and laboratory tests were significantly more costly in CAPD than in APD, whereas dialysis procedures were more expensive in the latter. Cost-utility indexes were significantly better in APD compared to CAPD. CONCLUSIONS: A significant cost-utility advantage of APD vs. CAPD was observed. The annual DMC per-patient were not different between groups but the HRQOL was better in the APD compared to the CAPD group.
Assuntos
Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/estatística & dados numéricos , Diálise Peritoneal/economia , Diálise Peritoneal/estatística & dados numéricos , Adulto , Idoso , Instituições de Assistência Ambulatorial/economia , Instituições de Assistência Ambulatorial/estatística & dados numéricos , Automação , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Admissão do Paciente/economia , Diálise Peritoneal/métodos , Diálise Peritoneal Ambulatorial Contínua/métodos , Estudos Prospectivos , Qualidade de Vida , Diálise Renal/economia , Diálise Renal/métodos , Diálise Renal/estatística & dados numéricos , Inquéritos e QuestionáriosRESUMO
OBJECTIVE: We set out to estimate the direct medical costs (DMCs) of peritoneal dialysis (PD) and to compare the DMCs for continuous ambulatory PD (CAPD) and automated PD (APD). In addition, DMCs according to age, sex, and the presence of peritonitis were evaluated. METHODS: Our retrospective cohort analysis considered patients initiating PD, calculating 2008 costs and, for comparison, updating the results for 2010. The analysis took the perspective of the Mexican Institute of Social Security, including outpatient clinic and emergency room visits, dialysis procedures, medications, laboratory tests, hospitalizations, and surgeries. RESULTS: No baseline differences were observed for the 41 patients evaluated (22 on CAPD, 19 on APD). Median annual DMCs per patient on PD were US$15 072 in 2008 and US$16 452 in 2010. When analyzing percentage distribution, no differences were found in the DMCs for the modality groups. In both APD and CAPD, the main costs pertained to the dialysis procedure (CAPD 41%, APD 47%) and hospitalizations (CAPD 37%, APD 32%). Dialysis procedures cost significantly more (p = 0.001) in APD (US$7 084) than in CAPD (US$6 071), but total costs (APD US$15 389 vs CAPD US$14 798) and other resources were not different. The presence of peritonitis increased the total costs (US$16 075 vs US$14 705 for patients without peritonitis, p = 0.05), but in the generalized linear model analysis, DMCs were not predicted by age, sex, dialysis modality, or peritonitis. A similar picture was observed for costs extrapolated to 2010, with a 10% - 20% increase for each component--except for laboratory tests, which increased 52%, and dialysis procedures, which decreased 3%, from 2008. CONCLUSIONS: The annual DMCs per patient on PD in this study were US$15 072 in 2008 and US$16 452 in 2010. Total DMCs for dialysis procedures were higher in APD than in CAPD, but the difference was not statistically significant. In both APD and CAPD, 90% of costs were attributable to the dialysis procedure, hospitalizations, and medications. In a multivariate analysis, no independent variable significantly predicted a higher DMC.
Assuntos
Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal/economia , Adulto , Idoso , Feminino , Humanos , Modelos Lineares , Masculino , México , Pessoa de Meia-Idade , Análise Multivariada , Peritonite/economia , Estudos RetrospectivosRESUMO
BACKGROUND: Home dialysis (peritoneal or haemodialysis) in any reasonable guise offers potential benefits compared with in-centre dialysis. Benefits may be overtly patient centred (independence, quality of life), outcome oriented (survival, resolution of left ventricular hypertrophy) or resource friendly (savings on staff costs). The priority placed on each of these areas is likely to vary from patient to patient, and possibly provider to provider. This is the one strength of home haemodialysis (HHD) rather than being viewed as a weakness, as it can offer different benefits to different people. Intuitively, more haemodialysis is better than less, and this is most realistically achieved at home. Indications are that both long nocturnal dialysis and short daily dialysis can offer real objective benefits. LITERATURE REVIEW: Critics argue correctly that there is a paucity of robust randomised controlled study data. The complexity of HHD regimens and practice and in-homogeneity of patients means such firm data are unlikely to be forthcoming. However, the positive reports both subjective and objective of patients dialysing at home, and results from the available research suggest that advantages may be seen purely with changing the location of dialysis to home, and independently with enhancing dialysis schedules. CONCLUSION: The logical conclusion is that patients undertaking haemodialysis at home should have at least the recommended minimum of four hours three times per week (or equivalent), preferably avoiding the long inter-dialytic interval, but beyond that rigid adherence to a schedule as dogma should be subjugated to patient choice and flexibility, albeit by prior agreement with supervising medical and nursing staff.
Assuntos
Hemodiálise no Domicílio/enfermagem , Falência Renal Crônica/enfermagem , Diálise Peritoneal Ambulatorial Contínua/enfermagem , Agendamento de Consultas , Redução de Custos/economia , Unidades Hospitalares de Hemodiálise/economia , Hemodiálise no Domicílio/economia , Humanos , Falência Renal Crônica/economia , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Avaliação de Resultados da Assistência ao Paciente , Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/psicologia , Qualidade de Vida/psicologia , Autocuidado/economia , Autocuidado/psicologia , Reino UnidoRESUMO
BACKGROUND: Longer, more frequent dialysis at home can improve life expectancy for patients with chronic kidney disease. Increased use of home dialysis therapies also benefits the hospital system, allowing for more efficient allocation of clinic resources. However, the Australian and New Zealand Data Registry statistics highlight the low uptake of home haemodialysis and peritoneal dialysis across Australia. OBJECTIVE: In August 2009, the Australia's HOME Network was established as a national initiative to engage and empower healthcare professionals working in the home dialysis specialty. The aim was to develop solutions to advocate for and ultimately increase the use of home therapies. This paper describes the development, achievement and future plan of the Australian HOME Network. ACHIEVEMENTS: Achievements to date include: a survey of HOME Network members to assess the current state of patient and healthcare professional-targeted education resources; development of two patient case studies and activities addressing how to overcome the financial burden experienced by patients on home dialysis. Future projects aim to improve patient and healthcare professional education, and advocacy for home dialysis therapies. CONCLUSION: The HOME Network is supporting healthcare professionals working in the home dialysis specialty to develop solutions and tools that will help to facilitate greater utilisation of home dialysis therapies.
Assuntos
Hemodiálise no Domicílio/enfermagem , Falência Renal Crônica/enfermagem , Equipe de Assistência ao Paciente/organização & administração , Diálise Peritoneal Ambulatorial Contínua/enfermagem , Austrália , Análise Custo-Benefício/economia , Estudos Transversais , Unidades Hospitalares de Hemodiálise/economia , Hemodiálise no Domicílio/economia , Hemodiálise no Domicílio/estatística & dados numéricos , Humanos , Falência Renal Crônica/epidemiologia , Nova Zelândia , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Educação de Pacientes como Assunto/economia , Diálise Peritoneal Ambulatorial Contínua/economia , Diálise Peritoneal Ambulatorial Contínua/estatística & dados numéricos , Desenvolvimento de Pessoal/economia , Revisão da Utilização de Recursos de Saúde/estatística & dados numéricosRESUMO
BACKGROUND: Despite the discrepancy in results from Spanish studies on the costs of dialysis, it is assumed that peritoneal dialysis (PD) is more efficient than haemodialysis (HD). OBJECTIVES: To analyse the costs and added value of HD and PD outsourcing agreements in Galicia, the medical transport for HD and the relationship between the cost of the agreement and the cost of consumables used in continuous ambulatory peritoneal dialysis (CAPD) with bicarbonate. METHODS: The cost of the outsourcing agreements and the staff was obtained from official publications. The cost of PD and medical transport were calculated using health service data for one month and extrapolating it to one year. The cost of CAPD consumables was provided by the suppliers. The added value was calculated from the investments generated for each agreement treating 40 patients. RESULTS: Expressed as patient/year, the mean costs for treatment were 21595 and 25664 in HD and PD, respectively. Medical transport varied between 3323 and 6338, while those of the CAPD agreement and consumables were 19268 and 12057, respectively. The added value was greater with the HD agreement, especially considering the jobs created. CONCLUSIONS: One cannot generalise that the cost of PD, which is significantly influenced by prescriptions, is lower than that of HD. It would be appropriate to review the additional cost to consumables in the CAPD agreement. The added value generated by dialysis agreements should be considered in future studies and in health planning. More controlled studies are needed to better understand this issue.